[Thymalin in the combined treatment of parkinsonism patients].
Musienko. G V GV
Key Findings
- Patients reported better physical and mental well‑being after thymalin treatment
- Motor symptoms like tremor, rigidity and slowed movement improved
- EEG showed reduced alpha power in front‑central brain areas, interpreted as improved cortical dynamics
Practical Outcomes
- Thymalin might offer some symptom relief for early Parkinson's, but the evidence is very limited—only 15 participants, no control group, and no dosing details. Biohackers should treat this as a preliminary hint rather than a ready‑to‑use protocol and wait for larger, controlled trials before adopting it.
Summary
A tiny study of 15 people with early‑stage Parkinson's disease gave them the peptide thymalin and saw modest improvements in overall well‑being, tremor, stiffness and movement speed, plus some brain‑wave changes that the authors think mean better brain function.
Abstract
Overall, fifteen patients with stage IB-2A (stages 1.5 to 2.5 as per UPDRS scale) idiopathic parkinsonism who ranged from 45 to 72 years old were examined before and after the course of treatment with thymalin. A positive time-related course was noted of the patients' general physical/mental well-being, parkinsonian triad of symptoms (tremor, rigidity, hypokinesia) associated with objective parameters characterizing the state of cerebral integrative functions (by the method of determining the biological age of the central nervous system). Efficacy of thymolin use is confirmed by EEG mapping; there has been established a significant decrement in the power of alpha rhythm in the anterocentral regions of the brain, which fact suggests to us an improvement in the cortical neurodynamics.
Study Information
pubmed
1999